FibroBiologics Advances Fibroblast Platform Into Hantavirus Pulmonary Syndrome With No Approved Treatments

With no approved antiviral or disease-modifying therapy for Hantavirus pulmonary syndrome, FibroBiologics is moving its fibroblast-based cell therapy platform into HPS disease models, a regulatory and manufacturing challenge that will test how preclinical ARDS data translates across a rare infectious disease indication.

HPS carries a case fatality rate exceeding 35–40% even under clinical management. The pathophysiology, uncontrolled inflammatory cascades, endothelial barrier dysfunction, and progressive pulmonary fibrosis, closely mirrors the acute respiratory failure mechanism the company has already studied in ARDS preclinical models. Those studies demonstrated fibroblast-mediated reduction of inflammatory cytokine signaling, restoration of endothelial barrier integrity, and promotion of tissue repair, the same pathogenic processes driving severe HPS.

FibroBiologics is now evaluating its platform in Hantavirus disease models with emphasis on cytokine modulation and endothelial permeability reduction. The company has indicated plans to open exploratory discussions with regulatory authorities to define a clinical development pathway for HPS patients. For regulatory affairs leads, the relevant question is how the company will frame its IND-enabling package given that HPS qualifies as a rare disease under existing orphan designation frameworks, a route that could accelerate early-stage regulatory dialogue.

From a manufacturing and process development standpoint, scaling fibroblast-based cell therapies for an infectious disease indication introduces distinct considerations around donor material characterisation, lot-to-lot consistency, and sterility assurance under 21 CFR Part 211 and applicable cell therapy GMP standards. The company holds more than 270 issued and pending patents across its fibroblast platform, suggesting an established IP and process foundation, though HPS-specific manufacturing protocols remain undisclosed at this stage.

Patients who survive acute HPS frequently develop chronic sequelae including pulmonary fibrosis and reduced lung capacity, broadening the potential therapeutic window beyond acute intervention and adding a chronic disease endpoint that could inform trial design and endpoint selection in future Phase I/II discussions with regulators.

The outcome of FibroBiologics' regulatory pre-submission meetings will be a measurable indicator of how authorities are prepared to handle fibroblast-based biologics in rare viral respiratory indications with no existing approved comparator.

Source: FibroBiologics, Inc. via GlobeNewswire press release, 11 May 2026.